Gossamer Bio Inc (NASDAQ:GOSS) CFO Bryan Giraudo purchased 1,000 shares of the company’s stock in a transaction that occurred on Thursday, May 30th. The stock was acquired at an average cost of $18.70 per share, with a total value of $18,700.00. The purchase was disclosed in a legal filing with the SEC, which is available through this hyperlink.
Gossamer Bio stock traded up $1.17 on Friday, hitting $22.18. 388,309 shares of the stock traded hands, compared to its average volume of 259,861. Gossamer Bio Inc has a 1 year low of $15.59 and a 1 year high of $25.06. The company has a debt-to-equity ratio of 0.02, a quick ratio of 19.79 and a current ratio of 19.79. The firm has a fifty day moving average of $20.17. The stock has a market capitalization of $1.38 billion and a price-to-earnings ratio of -0.98.
Gossamer Bio (NASDAQ:GOSS) last issued its quarterly earnings results on Tuesday, May 14th. The company reported ($0.90) earnings per share for the quarter, missing the consensus estimate of ($0.63) by ($0.27). On average, equities analysts forecast that Gossamer Bio Inc will post -2.61 EPS for the current year.
GOSS has been the subject of a number of research analyst reports. Svb Leerink initiated coverage on Gossamer Bio in a research note on Tuesday, March 5th. They issued an “outperform” rating and a $30.00 price target for the company. Zacks Investment Research raised Gossamer Bio from a “hold” rating to a “buy” rating and set a $23.00 price objective for the company in a research report on Tuesday, May 28th. Evercore ISI started coverage on Gossamer Bio in a research report on Tuesday, March 5th. They set an “outperform” rating and a $30.00 price objective for the company. Barclays started coverage on Gossamer Bio in a research report on Tuesday, March 5th. They set an “overweight” rating and a $27.00 price objective for the company. Finally, Leerink Swann started coverage on Gossamer Bio in a research report on Tuesday, March 5th. They set an “outperform” rating for the company. Six equities research analysts have rated the stock with a buy rating, The stock presently has a consensus rating of “Buy” and a consensus price target of $28.00.
About Gossamer Bio
Gossamer Bio, Inc, a clinical-stage biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology in the United States. It is developing GB001, an oral antagonist of prostaglandin D2 receptor 2 that is in Phase IIb clinical trial for the treatment of moderate-to-severe eosinophilic asthma, as well as that has completed Phase I clinical trial for chronic rhinosinusitis with nasal polyps, without nasal polyps, and chronic spontaneous urticarial; GB002, a platelet-derived growth factor, receptor kinase inhibitor that is in Phase I clinical trial for the treatment of pulmonary arterial hypertension; GB004, an oral small molecule that has completed Phase I clinical trial for the treatment of inflammatory bowel diseases; and GB1275, an oral small molecule for the treatment of oncology indications.
See Also: How to trade on quiet period expirations
Receive News & Ratings for Gossamer Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gossamer Bio and related companies with MarketBeat.com's FREE daily email newsletter.